Deep Sea Squid Caught on Camera Alive for the First Time. The Astonishing Footage Wasn't Planned
Scientists on a research expedition in the Southern Ocean captured the very first footage of a living Gonatus antarcticus squid
The colorful, three-foot squid species was only known to scientists previously by its remains in fishing nets and larger mammals' stomachs
The expedition also mapped ocean depths up to 4000 meters, collected samples of plant and animal life, and tracked a range of underwater terrainsScientists have captured the first images of a live Antarctic squid!
Researchers on an expedition in the Southern Ocean obtained the first known footage of a living Gonatus antarcticus squid, according to a press release from National Geographic on June 10. The three-foot-long specimen of the elusive species, which is only found in the icy waters around Antarctica, was filmed on Christmas Day 2024, and scientists are now sharing those findings with National Geographic and the world.
Footage of the mysterious creature was taken by chance. Scientists aboard the Schmidt Ocean Institute's research vessel, R/V Falkor (too), sent the vessel's remotely operated vehicle (ROV), SuBastian, to explore the depths of the frigid Southern Ocean. The ROV was in the right place at the right time and managed to film a passing Gonatus antarcticus squid. Before this, the cephalopod's existence was only known because its remains appeared in fishing nets and the stomachs of larger marine animals.
Images from the exciting encounter, which occurred 2152 meters (1.34 miles) deep in the Weddell Sea, show the vibrantly-colored squid with scratches and sucker marks on its body. Aside from these minor wounds, the squid appears to be in good health, according to National Geographic.
Footage of the squid also shows the large single central hook found on each tentacle, a characteristic researchers used to confirm that the sighting was indeed of a Gonatus antarcticus squid.
During the expedition, the research team also collected samples of plant life, organisms, sediment, and water, and mapped previously undiscovered depths that reached 4000 meters (roughly 2.5 miles deep), including terrains of "abyssal plains, hydrothermal vents, troughs, canyon walls and sea ice," per the release.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.
The Weddell Sea — part of the Southern Ocean, just southeast of the southern tip of South America — where the squid was found is considered "one of the few near-pristine ecosystems on the planet."
The R/V Falkor (too) and National Geographic Explorers went to the far-flung spot as part of the National Geographic and Rolex Perpetual Planet Ocean Expedition, which aims to provide a comprehensive scientific examination of the impact of climate change on the Earth's "few near-pristine ecosystems."
Footage of the squid and other moments from this expedition will be used in a future National Geographic documentary. To read more about this impressive squid sighting and the work it took to capture it, read more at natgeo.com.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
The famously unpredictable Bootids meteor shower is coming in June. Here's how to see it
Another meteor shower is on the horizon, starting later this month and lasting until the beginning of July. What's known as the Bootid meteor shower will soon occur. It happens every year at the same time. These meteors originate from from a comet called 7P/Pons-Winnecke, according to the Star Walk website. The Bootids are known for "unpredictable outbursts," according to National Geographic. So while they are generally a weaker shower, sometimes you get an outburst of shooting stars that makes the waiting worth it. "It showed unusual activity in 1998 (50-100 meteors per hour) and 2004 (20-50 meteors per hour). Another outburst was expected in 2010, but the shower produced less than ten meteors per hour," Star Walk said. Helping the show this year, the moon will be a waxing crescent, minimizing light interference at the peak. Here's what to know. The shower will be active from June 22 - July 2. The peak of this meteor shower will occur overnight from June 26-27, according to Star Walk. To find it, look for the constellation Bootes, also known as "The Herdsman" or "The Plowman," that the show is named after. It should be visible high in the western sky. In a past interview with USA Today Network, Tim Brothers, Massachusetts Institute of Technology technical instructor and observatory manager, told Wicked Local that seeing meteor showers is possible with the naked eye, but with any case of stargazing, it's much better if you're using a good telescope or a pair of binoculars. Meteors are essentially pieces of space rock, which are chunks of big comets, according to Meteor showers are "basically debris from the tails of comets," Richard Binzel, an MIT planetary sciences professor, told Wicked Local in a past interview. This article originally appeared on The Providence Journal: Bootids meteor shower 2025: How to watch 'unpredictable' June show
Yahoo
11 hours ago
- Yahoo
Scientists make stunning discovery hidden along 2,000-mile stretch of ancient Antarctic mountains: 'More dynamic … history than previously recognized'
Novel findings from University of Wisconsin, Oshkosh, geologist Timothy Paulsen and University of Colorado, Boulder, thermochronologist Jeff Benowitz have shed light on the complex and enigmatic history of Antarctica's ice sheets, The Debrief reported. Paulsen and Benowitz's research will appear in the August edition of the journal Earth and Planetary Science Letters. The study builds on a broader understanding of Antarctica's bedrock geology and introduces new insights. The Antarctic ice sheets "today blanket and mask the bedrock geology of Antarctica," the study's authors began. "However, when this bedrock landscape formed over many regions of Antarctica and how it has influenced ice sheet evolution remain as unresolved problems." Paulsen, Benowitz, and their research team set out to glean insights from a mysterious, "hidden" mountain range in Antarctica. Those massive mountains were first discovered during the British National Antarctic Expedition of 1901-1904. "Early exploration of the Antarctic continent revealed a surprising result, a 3,500-kilometer (2,175-mile) long mountain range with peaks over 4,500 meters (2.8 miles) crossing the Antarctic continental interior. This range was known as the 'great Antarctic horst' and is recognized today as the Transantarctic Mountains," Paulsen explained. Research examined periods of "exhumation" — a term in geology for periods when objects beneath or near the Earth's crust have moved closer to the surface — and their "potential influence on Paleozoic and Cenozoic glacial cycles" on the continent. The team analyzed an "exceptionally large data set from igneous rocks recovered from the Transantarctic Mountains," uncovering new evidence with respect to glacial cycles. Their findings hinted at a "much more dynamic Antarctic landscape history than previously recognized," which Paulsen expounded on. "Our new results suggest Transantarctic Mountain basement rocks experienced several punctuated mountain-building and erosion events, creating surfaces along which ancient rocks are missing. These events are curiously associated with major plate tectonic changes along the margins of Antarctica," he said. As is often the case, the team indicated that further research could reveal more about the continent's glacial cycles — which in turn can inform our broader knowledge of climate. An "older geologic history of the continent may have profoundly shaped the patterns of the modern landscape, which likely influenced cycles of glacial advance and retreat, and perhaps evolutionary steps in Earth's global ocean-atmosphere system," Paulsen stated. Do you think we still have a lot to learn from ancient cultures? Definitely Only on certain topics I'm not sure No — not really Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
18 hours ago
- Yahoo
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL patients IPH6501 is currently under investigation in a Phase 1/2 clinical study in relapsed and/or refractory (R/R) CD20+ B-cell non-Hodgkin lymphoma MARSEILLE, France, June 13, 2025--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an established standard of care for treatment-naïve patients with diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), two subtypes of B-NHL. The treatment landscape continues to evolve with novel approaches including T cell engagers, antibody-drug conjugates, their combination with standard of care therapies, and CAR-T cells. Yet, there remains an unmet medical need for patients ineligible, refractory to, or relapsing from these therapies. In preclinical in vitro models, IPH6501 demonstrated potent NK cell proliferation and tumor cell killing activity in DLBCL and FL patient samples, supporting its therapeutic potential in these indications. In preclinical in vivo xenografted mouse tumor models, IPH6501 showed strong activity in a rituximab-resistant model — even in the presence of rituximab highlighting their combination potential. Additionally, when combined with R-CHOP, IPH6501 showed enhanced antitumor efficacy, leading to tumor eradication that was maintained after treatment discontinuation. These findings underscore the potential of IPH6501 in improving standard-of-care R-CHOP treatment in previously untreated DLBCL and FL patients and support further evaluation of additional combination strategies in B-NHL. "Patients with R/R DLBCL and FL continue to face significant unmet medical needs. The encouraging activity observed in preclinical models with IPH6501, including in rituximab-resistant settings, suggests its potential to offer new treatment options for B-cell non-Hodgkin lymphoma. The enhanced antitumor activity in combination with R-CHOP could support further investigation in untreated patients. These findings support further clinical development aimed at improving outcomes in this challenging patient population," commented Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma. The poster will be available in the publication section of Innate Pharma's website. Abstract detailsAntitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004Session: Poster session 2Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CEST About ANKET® ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. About IPH6501 IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not the alpha subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule. This unique multispecific design provides targeted proliferation and activation signals to NK cells, promoting their cytotoxic activity against CD20 expressing malignant cells. IPH6501 has shown better antitumor efficacy compared to approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024). IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at Follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "intend," "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on Contacts For additional information, please contact:InvestorsInnate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 Media RelationsNewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@
